Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 188

1.

Determinants of adherence and consequences of the transition from adolescence to adulthood among young people with severe haemophilia (TRANSHEMO): study protocol for a multicentric French national observational cross-sectional study.

Resseguier N, Rosso-Delsemme N, Beltran Anzola A, Baumstarck K, Milien V, Ardillon L, Bayart S, Berger C, Bertrand MA, Biron-Andreani C, Borel-Derlon A, Castet S, Chamouni P, Claeyssens Donadel S, De Raucourt E, Desprez D, Falaise C, Frotscher B, Gay V, Goudemand J, Gruel Y, Guillet B, Harroche A, Hassoun A, Huguenin Y, Lambert T, Lebreton A, Lienhart A, Martin M, Meunier S, Monpoux F, Mourey G, Negrier C, Nguyen P, Nyombe P, Oudot C, Pan-Petesch B, Polack B, Rafowicz A, Rauch A, Rivaud D, Schneider P, Spiegel A, Stoven C, Tardy B, Trossaërt M, Valentin JB, Vanderbecken S, Volot F, Voyer-Ebrard A, Wibaut B, Leroy T, Sannie T, Chambost H, Auquier P.

BMJ Open. 2018 Jul 25;8(7):e022409. doi: 10.1136/bmjopen-2018-022409.

2.

The common VWF single nucleotide variants c.2365A>G and c.2385T>C modify VWF biosynthesis and clearance.

Mufti AH, Ogiwara K, Swystun LL, Eikenboom JCJ, Budde U, Hopman WM, Halldén C, Goudemand J, Peake IR, Goodeve AC, Lillicrap D, Hampshire DJ; European Group on von Willebrand disease (EU-VWD) and Zimmerman Program for the Molecular and Clinical Biology of von Willebrand disease (ZPMCB-VWD) Study Groups.

Blood Adv. 2018 Jul 10;2(13):1585-1594. doi: 10.1182/bloodadvances.2017011643.

3.

Fifth Åland Island conference on von Willebrand disease.

Berntorp E, Ågren A, Aledort L, Blombäck M, Cnossen MH, Croteau SE, von Depka M, Federici AB, Goodeve A, Goudemand J, Mannucci PM, Mourik M, Önundarson PT, Rodeghiero F, Szántó T, Windyga J.

Haemophilia. 2018 May;24 Suppl 4:5-19. doi: 10.1111/hae.13475.

PMID:
29687935
4.

Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A.

Calvez T, Chambost H, d'Oiron R, Dalibard V, Demiguel V, Doncarli A, Gruel Y, Huguenin Y, Lutz P, Rothschild C, Vinciguerra C, Goudemand J; for FranceCoag Collaborators.

Haematologica. 2018 Jan;103(1):179-189. doi: 10.3324/haematol.2017.174706. Epub 2017 Oct 12.

5.

New findings on inhibitor development: from registries to clinical studies.

Peyvandi F, Ettingshausen CE, Goudemand J, Jiménez-Yuste V, Santagostino E, Makris M.

Haemophilia. 2017 Jan;23 Suppl 1:4-13. doi: 10.1111/hae.13137. Review.

PMID:
27990784
6.

Summary report of the First International Conference on inhibitors in haemophilia A.

Lacroix-Desmazes S, Scott DW, Goudemand J, Van Den Berg M, Makris M, Van Velzen AS, Santagostino E, Lillicrap D, Rosendaal FR, Hilger A, Sauna ZE, Oldenburg J, Mantovani L, Mancuso ME, Kessler C, Hay CRM, Knoebl P, Di Minno G, Hoots K, Bok A, Brooker M, Buoso E, Mannucci PM, Peyvandi F.

Blood Transfus. 2017 Oct;15(6):568-576. doi: 10.2450/2016.0252-16. Epub 2016 Nov 25. No abstract available.

7.

Key insights to understand the immunogenicity of FVIII products.

Goudemand J, Peyvandi F, Lacroix-Desmazes S.

Thromb Haemost. 2016 Aug 31;116 Suppl 1:S2-9. doi: 10.1160/TH16-01-0048. Epub 2016 Aug 16.

PMID:
27528279
8.

Response to Wiewel-Verschueren S et al.: gynaecological and obstetrical bleeding in women with factor XI deficiency - a systematic review.

de Raucourt E, Bauduer F, Goudemand J.

Haemophilia. 2016 Sep;22(5):e435-6. doi: 10.1111/hae.13036. Epub 2016 Aug 3. No abstract available.

PMID:
27486008
9.

Von Willebrand Factor Multimers during Transcatheter Aortic-Valve Replacement.

Van Belle E, Rauch A, Vincent F, Robin E, Kibler M, Labreuche J, Jeanpierre E, Levade M, Hurt C, Rousse N, Dally JB, Debry N, Dallongeville J, Vincentelli A, Delhaye C, Auffray JL, Juthier F, Schurtz G, Lemesle G, Caspar T, Morel O, Dumonteil N, Duhamel A, Paris C, Dupont-Prado A, Legendre P, Mouquet F, Marchant B, Hermoire S, Corseaux D, Moussa K, Manchuelle A, Bauchart JJ, Loobuyck V, Caron C, Zawadzki C, Leroy F, Bodart JC, Staels B, Goudemand J, Lenting PJ, Susen S.

N Engl J Med. 2016 Jul 28;375(4):335-44. doi: 10.1056/NEJMoa1505643.

10.

Characterization of a novel large deletion caused by double-stranded breaks in 6-bp microhomologous sequences of intron 11 and 12 of the F13A1 gene.

Thomas A, Ivaškevičius V, Zawadzki C, Goudemand J, Biswas A, Oldenburg J.

Hum Genome Var. 2016 Feb 11;3:15059. doi: 10.1038/hgv.2015.59. eCollection 2016.

11.

A Laboratory Phenotype/Genotype Correlation of 1167 French Patients From 670 Families With von Willebrand Disease: A New Epidemiologic Picture.

Veyradier A, Boisseau P, Fressinaud E, Caron C, Ternisien C, Giraud M, Zawadzki C, Trossaert M, Itzhar-Baïkian N, Dreyfus M, d'Oiron R, Borel-Derlon A, Susen S, Bezieau S, Denis CV, Goudemand J; French Reference Center for von Willebrand disease.

Medicine (Baltimore). 2016 Mar;95(11):e3038. doi: 10.1097/MD.0000000000003038.

12.

A novel ELISA-based diagnosis of acquired von Willebrand disease with increased VWF proteolysis.

Rauch A, Caron C, Vincent F, Jeanpierre E, Ternisien C, Boisseau P, Zawadzki C, Fressinaud E, Borel-Derlon A, Hermoire S, Paris C, Lavenu-Bombled C, Veyradier A, Ung A, Vincentelli A, van Belle E, Lenting PJ, Goudemand J, Susen S.

Thromb Haemost. 2016 May 2;115(5):950-9. doi: 10.1160/TH15-08-0638. Epub 2016 Jan 21.

PMID:
26791163
13.

Response: Confounding by indication is unlikely to explain the higher inhibitor incidence in boys treated with a recombinant FVIII product.

Calvez T, Chambost H, Lutz P, Rothschild C, Goudemand J.

Blood. 2015 Jun 11;125(24):3817-9. doi: 10.1182/blood-2015-02-622167. No abstract available.

14.

Factor XI replacement for inherited factor XI deficiency in routine clinical practice: results of the HEMOLEVEN prospective 3-year postmarketing study.

Bauduer F, de Raucourt E, Boyer-Neumann C, Trossaert M, Beurrier P, Faradji A, Peynet J, Borg JY, Chamouni P, Chatelanaz C, Henriet C, Bridey F, Goudemand J; French Postmarketing Study Group.

Haemophilia. 2015 Jul;21(4):481-9. doi: 10.1111/hae.12655. Epub 2015 Mar 26.

15.

Expanding the Mutation Spectrum Affecting αIIbβ3 Integrin in Glanzmann Thrombasthenia: Screening of the ITGA2B and ITGB3 Genes in a Large International Cohort.

Nurden AT, Pillois X, Fiore M, Alessi MC, Bonduel M, Dreyfus M, Goudemand J, Gruel Y, Benabdallah-Guerida S, Latger-Cannard V, Négrier C, Nugent D, Oiron RD, Rand ML, Sié P, Trossaert M, Alberio L, Martins N, Sirvain-Trukniewicz P, Couloux A, Canault M, Fronthroth JP, Fretigny M, Nurden P, Heilig R, Vinciguerra C.

Hum Mutat. 2015 May;36(5):548-61. doi: 10.1002/humu.22776.

16.

Von Willebrand factor as a biological sensor of blood flow to monitor percutaneous aortic valve interventions.

Van Belle E, Rauch A, Vincentelli A, Jeanpierre E, Legendre P, Juthier F, Hurt C, Banfi C, Rousse N, Godier A, Caron C, Elkalioubie A, Corseaux D, Dupont A, Zawadzki C, Delhaye C, Mouquet F, Schurtz G, Deplanque D, Chinetti G, Staels B, Goudemand J, Jude B, Lenting PJ, Susen S.

Circ Res. 2015 Mar 27;116(7):1193-201. doi: 10.1161/CIRCRESAHA.116.305046. Epub 2015 Feb 10.

PMID:
25670067
17.

EQOFIX: a combined economic and quality-of-life study of hemophilia B treatments in France.

Polack B, Calvez T, Chambost H, Rothschild C, Goudemand J, Claeyssens S, Borel-Derlon A, Bardoulat I, Maurel F, Woronoff-Lemsi MC; EQOFIX Study Group.

Transfusion. 2015 Jul;55(7):1787-97. doi: 10.1111/trf.13016. Epub 2015 Feb 5.

PMID:
25652955
18.

Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A.

Calvez T, Chambost H, Claeyssens-Donadel S, d'Oiron R, Goulet V, Guillet B, Héritier V, Milien V, Rothschild C, Roussel-Robert V, Vinciguerra C, Goudemand J; FranceCoag Network.

Blood. 2014 Nov 27;124(23):3398-408. doi: 10.1182/blood-2014-07-586347. Epub 2014 Sep 24.

19.

Antibody-based prevention of von Willebrand factor degradation mediated by circulatory assist devices.

Rauch A, Legendre P, Christophe OD, Goudemand J, van Belle E, Vincentelli A, Denis CV, Susen S, Lenting PJ.

Thromb Haemost. 2014 Nov;112(5):1014-23. doi: 10.1160/TH14-02-0148. Epub 2014 Jul 17.

PMID:
25030452
20.

FXI concentrate use and risk of thrombosis.

Bolton-Maggs P, Goudemand J, Hermans C, Makris M, de Moerloose P.

Haemophilia. 2014 Jul;20(4):e349-51. doi: 10.1111/hae.12457. Epub 2014 May 2. No abstract available.

PMID:
24785157
21.

Colonoscopy in patients with haemophilia: the duration of clotting factor coverage must be adjusted to suit the procedure.

Tintillier V, Branche J, Maunoury V, Goudemand J, Renom P.

Haemophilia. 2013 Sep;19(5):e296-8. doi: 10.1111/hae.12174. Epub 2013 May 15. No abstract available.

PMID:
23672809
22.

Outcome of acquired haemophilia in France: the prospective SACHA (Surveillance des Auto antiCorps au cours de l'Hémophilie Acquise) registry.

Borg JY, Guillet B, Le Cam-Duchez V, Goudemand J, Lévesque H; SACHA Study Group.

Haemophilia. 2013 Jul;19(4):564-70. doi: 10.1111/hae.12138. Epub 2013 Apr 10.

PMID:
23574453
23.

VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease.

Eikenboom J, Federici AB, Dirven RJ, Castaman G, Rodeghiero F, Budde U, Schneppenheim R, Batlle J, Canciani MT, Goudemand J, Peake I, Goodeve A; MCMDM-1VWD Study Group.

Blood. 2013 Mar 21;121(12):2336-9. doi: 10.1182/blood-2012-09-455089. Epub 2013 Jan 24.

24.

Mutations in the A3 domain of von Willebrand factor inducing combined qualitative and quantitative defects in the protein.

Legendre P, Navarrete AM, Rayes J, Casari C, Boisseau P, Ternisien C, Caron C, Fressinaud E, Goudemand J, Veyradier A, Denis CV, Lenting PJ, Christophe OD.

Blood. 2013 Mar 14;121(11):2135-43. doi: 10.1182/blood-2012-09-456038. Epub 2013 Jan 18.

25.

Clinical and prognostic implications of low or high level of von Willebrand factor in patients with Waldenstrom macroglobulinemia.

Hivert B, Caron C, Petit S, Charpy C, Fankam-Siaka C, Lecocq S, Zawadzki C, Susen S, Rusu M, Duhamel A, Tournilhac O, Goudemand J, Morel P.

Blood. 2012 Oct 18;120(16):3214-21. doi: 10.1182/blood-2011-11-388256. Epub 2012 Aug 14.

26.

Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa).

Tiede A, Friedrich U, Stenmo C, Allen G, Giangrande P, Goudemand J, Hay C, Holmström M, Klamroth R, Lethagen S, McKenzie S, Miesbach W, Negrier C, Yuste VJ, Berntorp E.

J Thromb Haemost. 2011 Jun;9(6):1191-9. doi: 10.1111/j.1538-7836.2011.04293.x.

28.

Validation of the first commercial ELISA for type 2N von Willebrand's disease diagnosis.

Veyradier A, Caron C, Ternisien C, Wolf M, Trossaert M, Fressinaud E, Goudemand J.

Haemophilia. 2011 Nov;17(6):944-51. doi: 10.1111/j.1365-2516.2011.02499.x. Epub 2011 Mar 3.

PMID:
21371195
29.

A comparison between two semi-quantitative bleeding scales for the diagnosis and assessment of bleeding severity in type 1 von Willebrand disease.

Tosetto A, Rodeghiero F, Castaman G, Goodeve A, Federici AB, Batlle J, Meyer D, Goudemand J, Eikenboom J, Schneppenheim R, Budde U, Ingerslev J, Lethagen S, Hill FG, Peake I.

Haemophilia. 2011 Jan;17(1):165-6. doi: 10.1111/j.1365-2516.2010.02381.x. No abstract available.

PMID:
21199188
30.

Polymorphic variation within the VWF gene contributes to the failure to detect mutations in patients historically diagnosed with type 1 von Willebrand disease from the MCMDM-1VWD cohort.

Hampshire DJ, Burghel GJ, Goudemand J, Bouvet LC, Eikenboom JC, Schneppenheim R, Budde U, Peake IR, Goodeve AC; EU-VWD and ZPMCB-VWD study groups.

Haematologica. 2010 Dec;95(12):2163-5. doi: 10.3324/haematol.2010.027177. Epub 2010 Sep 17. No abstract available.

31.

The impact of bleeding history, von Willebrand factor and PFA-100(®) on the diagnosis of type 1 von Willebrand disease: results from the European study MCMDM-1VWD.

Castaman G, Tosetto A, Goodeve A, Federici AB, Lethagen S, Budde U, Batlle J, Meyer D, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Ingerslev J, Habart D, Hill F, Peake I, Rodeghiero F.

Br J Haematol. 2010 Nov;151(3):245-51. doi: 10.1111/j.1365-2141.2010.08333.x. Epub 2010 Aug 25.

PMID:
20738304
32.

Evaluation of an automated von Willebrand factor activity assay in von Willebrand disease.

Trossaërt M, Ternisien C, Lefrancois A, Llopis L, Goudemand J, Sigaud M, Fouassier M, Caron C.

Clin Appl Thromb Hemost. 2011 Nov-Dec;17(6):E25-9. doi: 10.1177/1076029610379848. Epub 2010 Aug 19.

PMID:
20724302
33.

Validation of a rapid test (VWF-LIA) for the quantitative determination of von Willebrand factor antigen in type 1 von Willebrand disease diagnosis within the European multicenter study MCMDM-1VWD.

Castaman G, Tosetto A, Cappelletti A, Goodeve A, Federici AB, Batlle J, Meyer D, Goudemand J, Eikenboom JC, Schneppenheim R, Budde U, Ingerslev J, Lethagen S, Hill F, Peake IR, Rodeghiero F.

Thromb Res. 2010 Sep;126(3):227-31. doi: 10.1016/j.thromres.2010.06.013. Epub 2010 Jul 22.

PMID:
20650506
34.

Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin-free method] demonstrates efficacy, safety and low-risk for immunogenicity in routine clinical practice.

Oldenburg J, Goudemand J, Valentino L, Richards M, Luu H, Kriukov A, Gajek H, Spotts G, Ewenstein B.

Haemophilia. 2010 Nov;16(6):866-77. doi: 10.1111/j.1365-2516.2010.02332.x.

PMID:
20579113
35.

von Willebrand factor variant p.Arg924Gln marks an allele associated with reduced von Willebrand factor and factor VIII levels.

Hickson N, Hampshire D, Winship P, Goudemand J, Schneppenheim R, Budde U, Castaman G, Rodeghiero F, Federici AB, James P, Peake I, Eikenboom J, Goodeve A; MCMDM-1VWD and ZPMCB-VWD study groups.

J Thromb Haemost. 2010 Sep;8(9):1986-93. doi: 10.1111/j.1538-7836.2010.03927.x.

36.

Intra-patient variability of thromboelastographic parameters following in vivo and ex vivo administration of recombinant activated factor VII in haemophilia patients. A multi-centre, randomised trial.

Kenet G, Stenmo CB, Blemings A, Wegert W, Goudemand J, Krause M, Schramm W, Kirchmaier C, Martinowitz U.

Thromb Haemost. 2010 Feb;103(2):351-9. doi: 10.1160/TH09-04-0212. Epub 2009 Dec 18.

PMID:
20024491
37.

AlphaIIbbeta3 integrin: new allelic variants in Glanzmann thrombasthenia, effects on ITGA2B and ITGB3 mRNA splicing, expression, and structure-function.

Jallu V, Dusseaux M, Panzer S, Torchet MF, Hezard N, Goudemand J, de Brevern AG, Kaplan C.

Hum Mutat. 2010 Mar;31(3):237-46. doi: 10.1002/humu.21179.

38.

Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system.

El-Ekiaby M, Sayed MA, Caron C, Burnouf S, El-Sharkawy N, Goubran H, Radosevich M, Goudemand J, Blum D, de Melo L, Soulié V, Adam J, Burnouf T.

Transfus Med. 2010 Feb;20(1):48-61. doi: 10.1111/j.1365-3148.2009.00963.x. Epub 2009 Sep 23.

PMID:
19778318
39.

Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM-1VWD study.

Eikenboom J, Hilbert L, Ribba AS, Hommais A, Habart D, Messenger S, Al-Buhairan A, Guilliatt A, Lester W, Mazurier C, Meyer D, Fressinaud E, Budde U, Will K, Schneppenheim R, Obser T, Marggraf O, Eckert E, Castaman G, Rodeghiero F, Federici AB, Batlle J, Goudemand J, Ingerslev J, Lethagen S, Hill F, Peake I, Goodeve A.

J Thromb Haemost. 2009 Aug;7(8):1304-12. doi: 10.1111/j.1538-7836.2009.03486.x. Epub 2009 Jun 30.

40.

Diluted Russell viper-venom time improves identification of antiphospholipid syndrome in a lupus anticoagulant-positive patient population.

Lambert M, Ferrard-Sasson G, Dubucquoi S, Hachulla E, Prin L, Hatron PY, Goudemand J, Boffa MC, Caron C.

Thromb Haemost. 2009 Mar;101(3):577-81.

PMID:
19277423
41.

Functional impairment of von Willebrand factor in hypertrophic cardiomyopathy: relation to rest and exercise obstruction.

Le Tourneau T, Susen S, Caron C, Millaire A, Maréchaux S, Polge AS, Vincentelli A, Mouquet F, Ennezat PV, Lamblin N, de Groote P, Van Belle E, Deklunder G, Goudemand J, Bauters C, Jude B.

Circulation. 2008 Oct 7;118(15):1550-7. doi: 10.1161/CIRCULATIONAHA.108.786681. Epub 2008 Sep 22.

PMID:
18809794
42.

Pharmacokinetics and pharmacodynamics of a new highly secured fibrinogen concentrate.

Négrier C, Rothschild C, Goudemand J, Borg JY, Claeyssens S, Alessi MC, Jaffry AC, Teboul C, Padrazzi B, Waegemans T.

J Thromb Haemost. 2008 Sep;6(9):1494-9. doi: 10.1111/j.1538-7836.2008.03076.x. Epub 2008 Jul 9.

43.

von Willebrand disease update: diagnostic and treatment dilemmas.

Bolton-Maggs PH, Lillicrap D, Goudemand J, Berntorp E.

Haemophilia. 2008 Jul;14 Suppl 3:56-61. doi: 10.1111/j.1365-2516.2008.01713.x.

PMID:
18510523
44.

Haemophilic arthropathy from A to Z. Introduction.

Négrier C, Goudemand J, Lambert T.

Haemophilia. 2008 Jul;14 Suppl 4:1-2. doi: 10.1111/j.1365-2516.2008.01731.x. No abstract available.

PMID:
18494685
45.

Properties of a concentrated minipool solvent-detergent treated cryoprecipitate processed in single-use bag systems.

Burnouf T, Caron C, Radosevich M, Goubran HA, Goudemand J, El-Ekiaby M.

Haemophilia. 2008 Sep;14(5):956-62. doi: 10.1111/j.1365-2516.2008.01797.x. Epub 2008 Jun 28.

PMID:
18565126
46.

Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD).

Haberichter SL, Castaman G, Budde U, Peake I, Goodeve A, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill FG, Montgomery RR.

Blood. 2008 May 15;111(10):4979-85. doi: 10.1182/blood-2007-09-110940. Epub 2008 Mar 14.

47.

Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD).

Budde U, Schneppenheim R, Eikenboom J, Goodeve A, Will K, Drewke E, Castaman G, Rodeghiero F, Federici AB, Batlle J, Pérez A, Meyer D, Mazurier C, Goudemand J, Ingerslev J, Habart D, Vorlova Z, Holmberg L, Lethagen S, Pasi J, Hill F, Peake I.

J Thromb Haemost. 2008 May;6(5):762-71. doi: 10.1111/j.1538-7836.2008.02945.x. Epub 2008 Mar 1.

48.

Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD.

Castaman G, Lethagen S, Federici AB, Tosetto A, Goodeve A, Budde U, Batlle J, Meyer D, Mazurier C, Fressinaud E, Goudemand J, Eikenboom J, Schneppenheim R, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Pasi J, Hill F, Peake I, Rodeghiero F.

Blood. 2008 Apr 1;111(7):3531-9. doi: 10.1182/blood-2007-08-109231. Epub 2008 Jan 29.

49.

Inhibitor development in haemophilia A: the role of von Willebrand factor/factor VIII concentrates.

Goudemand J.

Haemophilia. 2007 Dec;13 Suppl 5:47-51. doi: 10.1111/j.1365-2516.2007.01571.x.

PMID:
18078397
50.

Supplemental Content

Loading ...
Support Center